ImmunoGen Message Board - Msg: 28107075

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rjk01 who wrote (5494)	4/25/2012 11:58:34 PM
From: Gary Mohilner	Read Replies (1) of 5665

You're wrong about that, when AEZS is put on notice by Nasdaq they have 6 months to come into compliance without requesting more time, and based on their financial position should qualify for an additional 6 months extension. I don't see it being a problem as long as they execute their plan to file the NDA on AEZS-130 and start the Phase III on AEZS-108. For now they wait KERX's decision on the MM Trial with Perifosine. KERX's website has eliminated mention of the colon cancer trial, but shows the MM Trial and other Phase I and II's for Perifosine in their pipeline, here's a link: keryx.com Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next